NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DXC Technology Company (NYSE: DXC) between May 26, 2021 and May 16, 2024, both dates inclusive (the "Class Period"), of the important October 1, 2024 lead plaintiff deadline. SO WHAT: If you purchased DXC common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

文章核心观点 - 公司Outset Medical被指在2022年8月1日至2024年8月7日期间做出了虚假或误导性陈述,未能披露以下信息[4]: 1) Tablo产品被用于连续性肾脏替代治疗,这并非美国FDA批准的适应症之一 2) 因此Outset Medical很可能需要提交额外的510(k)申请用于Tablo产品 3) 存在Outset Medical可能暂停Tablo产品销售直至FDA批准新适应症的重大风险 4) Outset Medical缺乏执行Tablo销售增长的销售团队和流程 5) 上述因素将对公司的收入增长产生不利影响 6) 因此公司关于业务、运营和前景的积极声明存在重大误导性和缺乏合理依据 根据目录分别总结 1. 文章概述 - 罗森律师事务所代表Outset Medical公司证券购买者提起集体诉讼[1][2] - 诉讼时间范围为2022年8月1日至2024年8月7日[1] - 如果您在此期间购买了Outset Medical证券,您可能有权获得赔偿[1][2] 2. 诉讼详情 - 公司涉嫌在上述期间做出虚假或误导性陈述,未能披露以下信息[4]: 1) Tablo产品被用于连续性肾脏替代治疗,这并非FDA批准的适应症 2) 公司很可能需要提交额外的510(k)申请用于Tablo产品 3) 存在公司可能暂停Tablo产品销售的重大风险 4) 公司缺乏执行Tablo销售增长的销售团队和流程 5) 上述因素将对公司的收入增长产生不利影响 6) 因此公司关于业务、运营和前景的积极声明存在重大误导性和缺乏合理依据 3. 加入诉讼 - 如果您在上述期间购买了Outset Medical证券,您可以通过以下方式加入集体诉讼[2][5]: 1) 访问https://rosenlegal.com/submit-form/?case_id=17760 2) 致电Phillip Kim律师,电话866-767-3653 3) 发送电子邮件至case@rosenlegal.com

集体诉讼案件概述 - Rosen Law Firm于2024年9月1日宣布，已代表在2022年8月9日至2024年4月1日期间购买Verve Therapeutics, Inc.证券的购买者提起集体诉讼 [1] - 诉讼称，被告在整个集体诉讼期间做出了虚假和/或误导性陈述，和/或未能披露相关信息，导致投资者遭受损失 [5] 诉讼指控的具体内容 - 被告未充分披露其基因编辑药物VERVE-101的Heart-1 1b期临床试验被暂停的具体情况，该药物旨在通过单次治疗永久关闭肝脏中的PCSK9基因以降低低密度脂蛋白胆固醇 [5] - 被告夸大了其专有脂质纳米颗粒递送系统的潜在益处 [5] - 因此，被告关于其业务、运营和前景的陈述在所有相关时间均存在重大虚假和误导性和/或缺乏合理依据 [5] 诉讼程序相关安排 - 希望担任首席原告的个人必须在2024年10月28日之前向法院提出动议 [1][3] - 投资者可以通过指定网站、电话或电子邮件加入Verve Therapeutics集体诉讼 [3][6] - 在集体诉讼获得认证之前，投资者除非自行聘请律师，否则并无法律代表，投资者可选择自己的律师或选择不作为 [7] 原告律师事务所信息 - Rosen Law Firm是一家全球投资者权益律师事务所，专注于证券集体诉讼和股东衍生诉讼 [4] - 该律所曾达成针对中国公司的有史以来最大的证券集体诉讼和解，并在2017年因证券集体诉讼和解数量被ISS Securities Class Action Services排名第一，自2013年以来每年均位列前四 [4] - 该律所已为投资者追回数亿美元，仅在2019年就为投资者确保了超过4.38亿美元 [4]

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of CrowdStrike Holdings, Inc. (NASDAQ: CRWD) between November 29, 2023 and July 29, 2024, both dates inclusive (the "Class Period"), of the important September 30, 2024 lead plaintiff deadline. SO WHAT: If you purchased CrowdStrike Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Period"), of the important October 15, 2024 lead plaintiff deadline. SO WHAT: If you purchased Ardelyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of lululemon athletica inc. (NASDAQ: LULU) between December 7, 2023 and July 24, 2024, both dates inclusive (the "Class Period"), of the important October 7, 2024 lead plaintiff deadline. SO WHAT: If you purchased lululemon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange ...

NEW YORK, Aug. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sprinklr, Inc. (NYSE: CXM) between March 29, 2023 and June 5, 2024, both dates inclusive (the "Class Period"), of the important October 15, 2024 lead plaintiff deadline. SO WHAT: If you purchased Sprinklr securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

NEW YORK, Aug. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of American Airlines Group Inc. (NASDAQ: AAL) between January 25, 2024 and May 28, 2024, both dates inclusive (the "Class Period"), of the important September 16, 2024 lead plaintiff deadline. SO WHAT: If you purchased American Airlines securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

NEW YORK, Aug. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, Aug. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 15, 2024. SO WHAT: If you purchased Ardelyx securities during the Class ...